- Home
- PYXS vs HOWL Comparison
PYXS vs HOWL Comparison
Compare PYXS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYXS | HOWL |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 64.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PYXS | HOWL |
|---|---|---|
| Price | $1.78 | $0.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $6.75 | $6.50 |
| AVG Volume (30 Days) | ★ 2.6M | 958.7K |
| Earning Date | 11-03-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,820,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.53 |
| 52 Week High | $5.55 | $2.38 |
Technical Indicators
Market Signals| Indicator | PYXS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 29.20 |
| Support Level | $1.03 | $0.53 |
| Resistance Level | $2.17 | $0.59 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 66.22 | 15.65 |
Price Performance
Historical ComparisonAbout PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.